Who are Aeriepharma's investors?

Aeriepharma's investors include Alta Partners, Avoro Capital Advisors, Foresite Capital, OUP (Osage University Partners), Sofinnova Ventures.

How much funding has Aeriepharma raised?

Aeriepharma has disclosed $125M raised across 1 round.

Where is Aeriepharma headquartered?

Aeriepharma is headquartered in Bedminster, US.

Aeriepharma

Bedminster, US · 5 known investors

Aerie Pharmaceuticals develops ophthalmic pharmaceutical products including Rocklatan and Rhopressa for glaucoma and ocular hypertension, and AR-15512 for dry eye disease. The company serves eye care professionals and patients in the global ophthalmic pharmaceutical market.

Biotech Healthtech Medical Devices

Founders & leadership

DAVID GRYSKANamed on SEC filing

VICENTE ANIDONamed on SEC filing

MURRAY GOLDBERGNamed on SEC filing

ANAND MEHRANamed on SEC filing

BRIAN LEVYNamed on SEC filing

GERALD CAGLENamed on SEC filing

CASEY KOPCZYNSKINamed on SEC filing

DENNIS HENNERNamed on SEC filing

JAMES MAZZONamed on SEC filing

RICHARD RUBINONamed on SEC filing

GEOFFREY DUYKNamed on SEC filing

THOMAS MITRONamed on SEC filing

Investors · 5

Alta PartnersJackson · $1M – $12M

Avoro Capital AdvisorsNew York

Foresite CapitalWest Hollywood

OUP (Osage University Partners)Bala Cynwyd · $1M – $20M

Sofinnova VenturesMenlo Park · $100K – $15M

Reported raises · per SEC filings

Form D private placements

$125M disclosed across 1 round · 2014

▶$125MraisedSep 2014 · 5 investors · Pharmaceuticals

Rule 506(b)

Officers, directors & promoters on the filing

DAVID GRYSKADirector
VICENTE ANIDOExecutive Officer, Director
MURRAY GOLDBERGDirector
ANAND MEHRADirector
BRIAN LEVYExecutive Officer
GERALD CAGLEDirector
CASEY KOPCZYNSKIExecutive Officer
DENNIS HENNERDirector
JAMES MAZZODirector
RICHARD RUBINOExecutive Officer
GEOFFREY DUYKDirector
THOMAS MITROExecutive Officer

Offering amount: $125M
Amount sold: $125M
First sale: Sep 2014
Incorporated: Corporation, Delaware
Federal exemptions: 06b

Full filing on SEC EDGAR ↗

Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.

Frequently asked questions

What does Aeriepharma do?: Aerie Pharmaceuticals develops ophthalmic pharmaceutical products including Rocklatan and Rhopressa for glaucoma and ocular hypertension, and AR-15512 for dry eye disease. The company serves eye care professionals and patients in the global ophthalmic pharmaceutical market.
Who are Aeriepharma's investors?: Aeriepharma's investors include Alta Partners, Avoro Capital Advisors, Foresite Capital, OUP (Osage University Partners), Sofinnova Ventures.
How much funding has Aeriepharma raised?: Aeriepharma has disclosed $125M raised across 1 round.
Where is Aeriepharma headquartered?: Aeriepharma is headquartered in Bedminster, US.